The emergence of imatinib resistance has led to a search for additional inhibitors of BCR-Abl, and the second generation inhibitors dasatinib and nilotinib were recently approved for use in CML patients resistant to imatinib, as well as for front-line therapy [8], [9]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.